Skip to main content

Advertisement

Figure 3 | SpringerPlus

Figure 3

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

Figure 3

Progression-free survival (PFS) and overall survival (OS) according to relapse-free survival (RFS) in the docetaxel monotherapy group. (A) PFS: RFS <6 months, median PFS = 2.2 months; RFS ≥6 months, median PFS = 2.8 months. (B) OS: RFS <6 months, median OS = 12.0 months; RFS ≥6 months, median OS = 16.3 months.

Back to article page